AirBoss Q2 2026 slides: defense, specialty products drive margin gains

AirBoss reported Q2 EPS of $0.09 vs $0.06 consensus and revenue of $107.9M vs $104.2M, with adjusted EBITDA rising to $9.5M from $7.3M and gross margin expanding 100 bps to 17.4%. The company also highlighted three consecutive quarters of volume growth and management is “fairly optimistic” on new customer wins, though it expects uneven growth and potentially softer sequential demand in Q3. Positively, shares rose 7.7% after hours, but operating cash flow fell to $1.8M CAD (from $12.9M CAD) and net debt increased to $72.9M CAD, reflecting ongoing cash/deleveraging pressure despite improving profitability.

Analysis

This is less a “beat” than evidence that BOS’s mix shift is finally producing operating leverage. For a sub-$200mm market cap name, small changes in gross margin and defense mix can re-rate the equity quickly, but the market should not pay for this as if it were already a durable secular compounder. The second-order winner is domestic, compliance-sensitive supply: OEMs, defense buyers, and tier-1s that value North American redundancy. The losers are lower-cost offshore compounders and weaker secondary suppliers that cannot match local lead times or procurement requirements.

The key risk is that the next leg of the story is timing, not direction. Q3 seasonality, post-contract margin normalization, and working-capital drag can easily flatten the optics before the silicone line and next-generation product become meaningful contributors. If cash conversion does not improve over the next 1-2 quarters, the equity can give back a meaningful chunk of the post-earnings move even if revenue stays positive. Falsifiers: sequential volume deceleration, no visible margin lift from specialty products by year-end, or another step-up in net debt without corresponding EBITDA growth.

Contrarian view: consensus may be underestimating how much “domestic redundancy” can matter in an environment of tariff noise and supply-chain de-risking, which supports a longer runway for share gains. But the market may also be overpricing the turnaround before free cash flow proves it can self-fund. The right read here is staged confirmation, not heroics: use pullbacks to build exposure, not momentum spikes to chase.

Key Decisions for Investors

• Initiate a tactical long in BOS.TO on a pullback into the CAD 6.80-6.95 range; target CAD 8.20-8.50 over 1-3 months if Q3 commentary confirms continued volume growth and mix improvement.
• Set a hard risk stop on BOS.TO below CAD 6.40, or sooner if management signals Q3 volume flattening or margin giveback from defense contract roll-off.
• For existing holders, sell into strength above CAD 7.80-8.00 and wait for the next operating-cash-flow print; the stock is likely to be range-bound until the market sees FCF conversion rather than just EBITDA recovery.
• Watch-list, not buy-list: if silicone starts showing up in segment mix by the next two quarters and operating cash flow inflects higher, add for a 6-18 month structural re-rating.
• Avoid a crowded long/short pair unless you have a clean domestic-compounder hedge; the cleaner expression is a small, opportunistic long with strict downside discipline rather than a leveraged relative-value bet.